

Kratom Compliance Review Florida

July 29, 2026 | 12:38:31 AM



Compliant
 All reviewed requirements passed.

● Passing
37

● Needs Attention
0

● Critical
0

REVIEW SUMMARY

STATE

FLORIDA

COMPANY NAME

MOON WALKER

PRODUCT NAME

MOON WALKER KRATOM CHEWABLE TABLET 250MG
MIGHTY MANGO

SKU

—

SUBSTANCE

KRATOM

PRODUCT TYPE

CAPSULE

COMPLIANCE STATUS

COMPLIANT

PRODUCT IMAGES



Mighty Mango Back.pdf



Mighty Mango Front.pdf

CERTIFICATE OF ANALYSIS (COA)



COA MIGHTY MANGO.pdf

FINDINGS

● Passing

1. Net Quantity Statement Placement on Principal Display Panel

Rule Summary: Net quantity must appear on the principal display panel in the bottom 30% unless the panel is 5 square inches or less.

Suggested Fix: Add a proper net quantity of contents statement (e.g. 'Net Contents: 4 Tablets (1000 mg / 1 g)') in the bottom 30% of the front display panel, showing the count and, for the weight, both metric and US customary units.

Ref: 21CFR101.7

2. Supplement Facts Panel with Serving Information and Alkaloid Amounts

Rule Summary: A supplement or nutrition facts panel must disclose serving size, servings per container, and amount per serving of each alkaloid or compound matching the COA.

Suggested Fix: The Supplement Facts panel is present with serving size and servings per container. Remove the "Key Ingredients" header from the left column, leaving ingredient names unheaded, and keep "Amount Per Serving" as the sole header on the right column; move "Batch Number" and "Expiration Date" out of the Supplement Facts box and onto the panel below it, near the barcode.

Ref: 21CFR101.36

3. Addiction Disclaimer Warning for Kratom Alkaloids

Rule Summary: The label must include a substantive addiction disclaimer for kratom alkaloids, not buried, in a legible font of at least 6-point.

Suggested Fix: Add, in its own clearly separated paragraph: "WARNING: This product contains kratom alkaloids that may have habit-forming potential. Prolonged or high-dose use may lead to tolerance, dependence, addiction, withdrawal symptoms, or serious injury. Not intended for long-term or daily use. Use only as directed."

Ref: FL-WarningStatements-AddictionDisclaimer-Recommended

4. PPM and Method Detection Limit Statement Beneath Fact Panel

Rule Summary: Include a statement disclosing PPM and method detection limit beneath the fact panel when 7-OH is non-detect or near MDL.

Evidence: The Supplement Facts panel states 7-Hydroxymitragynine at '309.20 parts per million (PPM) ON DRY WEIGHT BASES', but no separate supplemental PPM/method detection limit (MDL) statement appears beneath the fact panel, so this near-MDL supplemental disclosure rule does not apply.

Ref: FL-7OH-WordingBeneathFactPanel-Recommended

5. Adverse Reactions Poison Control Statement

Rule Summary: The label must include an adverse-events or poison control statement with the number 1-800-222-1222.

Suggested Fix: Add an adverse-events/poison control statement including the Poison Control number, for example: 'In case of adverse reactions, seek immediate medical attention or contact a Poison Control Center at 1-800-222-1222.'

Ref: FL-WarningStatements-PoisonControl-Recommended

6. URL for Company or Brand

Rule Summary: The label must display a URL for the company or brand.

Evidence: The label shows a contact email ('contact@moonwalkerkratom.com') on the information panel.

Ref: FL-CompanyURL-Recommended

7. Do Not Combine with Alcohol Warning

Rule Summary: The label must include a warning not to use the product with alcohol, medicine, or other intoxicating substances.

Suggested Fix: Add a do-not-combine warning to the label, for example: 'Do not use this product with alcohol, medicine, or other intoxicating substances.'

Ref: FL-WarningStatements-DoNotCombineAlcohol-Recommended

8. Underage Use Warning in All Caps and Bold

Rule Summary: The label must include an underage-use warning with at least one in all caps and bold, without referencing 18+ or younger legal ages.

Evidence: The label includes underage-use warnings ('For adults 21+ only. Keep out of reach of children.') with no references to ages under 21, but none of these warnings appear in all CAPS and bold as required.

Suggested Fix: Add at least one underage-use warning rendered in all CAPS and bold, for example 'MUST BE 21 YEARS OR OLDER TO PURCHASE OR POSSESS THIS PRODUCT.'

Ref: FL-WarningStatements-UnderageUse-Recommended

9. Minimum Font Size and Proportions for Required Label Text

Rule Summary: Required information on the principal display panel and information panel must be at least 1/16 inch high, letters no more than three times as high as wide, with sufficient contrast.

Evidence: The required text (Supplement Facts, warnings, disclaimers, and PDP information) is present on the label, but exact letter height (1/16 inch minimum), the 3x height-to-width ratio, and contrast cannot be measured from a flat image.

Suggested Fix: Confirm on the physical printed label that all required text — including the Supplement Facts panel, all warnings, and disclaimers — is at least 1/16 inch in height, that letters are no more than three times as high as they are wide, and that text prints with sufficient contrast against the orange/yellow background (note the small light-colored warning text over the busy lower image on the front panel as a potential contrast concern).

Ref: 21CFR101.2

10. Directions or Recommended Use Statement

Rule Summary: The label must include a directions or recommended use statement preceded by either "Directions:" or "Recommended Use:".

Suggested Fix: Add the heading "Directions:" before the usage instructions, e.g., "Directions: Take 1/4 tablet (62.5 mg). Do not exceed one serving every 48 hours."

Ref: FED-Directions-Recommended

11. Batch Number Display

Rule Summary: The label must display a batch number identifying the production lot.

Evidence: The label displays a batch number identifying the production lot ('027101006MG') in the Supplement Facts panel.

Ref: FL-BatchNumber-Recommended

12. 7-OH Concentration PPM and Dry Weight Basis Disclosure

Rule Summary: The 7-OH concentration must be stated in parts per million and denoted on a dry weight basis.

Evidence: The label states the 7-Hydroxymitragynine concentration as '309.20 parts per million (PPM) ON DRY WEIGHT BASES', which matches the lab report's dry-weight value of 309.20 ppm.

Ref: 5KER26-1(2)(b)

13. Expiration Date

Rule Summary: The label must display an expiration date.

Evidence: The label displays an expiration date of '12/2028' in the Supplement Facts panel.

Ref: FL-ExpirationDate-Recommended

14. FDA Disclaimer Statement

Rule Summary: The FDA disclaimer must appear stating that statements have not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent disease, on its own line separate from other warnings.

Evidence: Replace the current single-sentence FDA Disclaimer with: "FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Ref: FL-WarningStatements-FDADisclaimer

15. Pseudoindoxyl Concentration Declaration

Rule Summary: If pseudoindoxyl is present on the COA, its concentration must be declared on the label.

Evidence: The lab report (COA) does not list pseudoindoxyl anywhere in its tested analytes (it reports mitragynine, paynantheine, speciogynine, speciociliatine, 7-hydroxymitragynine, mitraphylline, and moisture). Since pseudoindoxyl is not shown as present, there is nothing that must be declared on the label.

Ref: 5KER26-1(3)

16. 21+ Age Restriction Warning

Rule Summary: The label must include a clear, easy-to-read warning or symbol indicating that kratom products may not be sold to persons under 21.

Evidence: The label includes a 21+ adult-use warning: the Safety & Legal Disclaimer states 'For adults 21+ only.' and the Product Description states the product is 'Designed for adult use only.'

Ref: FL-21PlusWarning-Recommended

17. Responsible Use and Misuse Disclaimer

Rule Summary: The label must include a responsible-use or misuse disclaimer.

Evidence: The Legal Disclaimer states: "you assume full responsibility for any adverse events and/or health complications that may result from its use" — a blanket waiver not tied to misuse, which may be deemed unenforceable or replace the current Legal Disclaimer sentence with the short-form wording: "Notice: Use only as directed. The manufacturer and distributor are not responsible for effects resulting from misuse or use inconsistent with labeled instructions."

Ref: FL-WarningStatements-ResponsibleUseMisuse-Recommended

18. Pregnancy and Nursing Warning

Rule Summary: The label must include a warning that the product is not safe for persons who are pregnant or nursing.

Evidence: The label includes a pregnancy and nursing warning within the Safety & Legal Disclaimer: 'Do not use if pregnant, nursing, or operating heavy machinery.'

Ref: FL-WarningStatements-PregnancyNursing-Recommended

19. Consult Healthcare Professional Before Use Warning

Rule Summary: Label must include a warning to consult a healthcare professional before use in a clearly legible font not substantially smaller than other text.

Evidence: The label includes a consult-a-healthcare-professional warning within the Safety & Legal Disclaimer: 'Consult your healthcare provider before use, especially if you have medical conditions or are taking medication.' It appears alongside several other warnings (age restriction, keep out of reach of children, pregnancy/machinery caution).

Ref: FL-WarningStatements-ConsultMedical-Recommended

20. Do Not Exceed Recommended Serving Warning

Rule Summary: The label must include a warning not to exceed the recommended use or serving.

Evidence: The label includes a do-not-exceed-serving warning: the Usage Guidelines state 'Consume no more than one serving every 48 hours. Effects may be delayed by up to two hours.'

Ref: FL-WarningStatements-DoNotExceedServing-Recommended

21. 7-Hydroxymitragynine Concentration Declaration in PPM on Dry-Weight Basis

Rule Summary: Kratom products must declare the 7-OH concentration and its derivatives in parts per million on a dry-weight basis for the package's net contents.

Evidence: The Supplement Facts panel declares 7-Hydroxymitragynine at '309.20 parts per million (PPM) ON DRY WEIGHT BASES', satisfying the required PPM value on a dry-weight basis.

Ref: 5KER26-1(1)

22. Machinery Use Warning

Rule Summary: The label must include a warning against driving or operating heavy machinery after consuming the product.

Evidence: The label includes a machinery-use warning in the Safety & Legal Disclaimer: 'Do not use if pregnant, nursing, or operating heavy machinery.'

Ref: FL-WarningStatements-MachineryUse-Recommended

23. 7-OH Limit COA and QR Code Verification

Rule Summary: Products must be below 400 ppm 7-OH on a dry weight basis, with a scannable QR code linking to the COA confirming this limit.

Evidence: The label includes a scannable QR code (bottom-left of the Supplement Facts panel), and the lab report (COA) shows 7-OH at 309.20 ppm on a dry-weight basis, below the 400 ppm limit (marked PASS).

Ref: FL-COA-QRCode-Recommended

24. 7-Hydroxymitragynine Concentration Display Requirements

Rule Summary: The 7-Hydroxymitragynine concentration must be affixed to the package clearly and conspicuously using appropriate color, type size, and contrasting background, and not solely on the container bottom.

Evidence: The 7-Hydroxymitragynine concentration ('309.20 parts per million (PPM) ON DRY WEIGHT BASES') is printed within the Supplement Facts panel on the back label in dark type against a lighter orange background, not solely on the bottom of the container. This value matches the lab report (COA) dry-weight result of 309.20 ppm.

Ref: 5KER26-1(2)(c)

25. Warning Statement Font and Legibility Requirements

Rule Summary: Warning statements must use clearly legible font not substantially smaller than other text and may not rely on website disclaimers for in-store products.

Evidence: The warning statements are present as readable body text consistent in size with the label's other content, and none direct consumers to a website for full disclaimers. The label carries substantive warnings, including 'For adults 21+ only. Keep out of reach of children,' a healthcare-provider caution, and the FDA disclaimer.

Ref: FL-WarningStatements-General-Recommended

26. Ingredient List Format and Placement Requirements

Rule Summary: Ingredient list must be on the same panel as manufacturer name/address, use at least 1/16 inch type, list ingredients by common/usual names in descending order by weight, and declare allergens.

Evidence: The label includes an 'Other Ingredients' list by common name (Microcrystalline Cellulose, Dicalcium Phosphate, Dextrose Monohydrate, Natural Flavoring, Silicone Dioxide, Sucralose, Magnesium Stearate) on the same panel as the 'Manufactured for: Moon Walker LLC, 8 The Green Ste B, Dover DE 19901' statement.

Ref: 21CFR101.4

27. Storage Instructions Statement

Rule Summary: The label must include a storage instructions statement such as "store in a cool, dry place" or "refrigerate after opening" as applicable.

Evidence: The label includes a storage instructions statement: 'Store in a cool, dry place away from direct sunlight.'

Ref: FED-StorageInstructions-Recommended

28. Major Food Allergen Declaration

Rule Summary: The label must declare all major food allergens present in the food using their common or usual names.

Evidence: The ingredient lists (Other Ingredients) show no major food allergens, so no allergen declaration is required.

Ref: 21USC343(w)

29. Name and Street Address of Manufacturer, Packer, or Distributor

Rule Summary: The label must conspicuously state the name and full street address of the manufacturer, packer, or distributor, with appropriate prefix if not the manufacturer.

Evidence: The label states 'Manufactured for: Moon Walker LLC, 8 The Green Ste B, Dover DE 19901,' providing the required name and full street address with the proper 'Manufactured for:' disclosure.

Ref: 21CFR101.5

30. Nutrition Facts Panel for Kratom Marketed as Conventional Food

Rule Summary: Kratom products marketed as conventional food must bear a Nutrition Facts panel per 21 CFR §101.9 format with serving size, servings per container, calories, and required nutrients.

Evidence: The product is marketed as a 'DIETARY SUPPLEMENT' (chewable tablets) and bears a Supplement Facts panel, not a conventional food, so the Nutrition Facts requirement does not apply.

Ref: 21CFR101.9

31. Statement of Identity Location, Size, and Format

Rule Summary: The statement of identity must appear on the PDP in bold type at least half the size of the largest print on both outer and inner packaging.

Evidence: The front panel (PDP) clearly identifies the product as 'KRATOM EXTRACT' with '4x Chewable Tablets', which serves as the statement of identity apart from the 'Moon Walker' brand name.

21CFR101.3

32. Statement of Identity for Dietary Supplements

Rule Summary: The statement of identity must include the term "dietary supplement" or replace "dietary" with the name of the dietary ingredient.

Evidence: The front panel of the label displays the required term 'DIETARY SUPPLEMENT' as part of the statement of identity.

Ref: 21CFR101.3(g)

33. Kratom Product 7-OH Maximum Concentration Limit

Rule Summary: Kratom products must not contain 7-hydroxymitragynine above 400 ppm on a dry-weight basis.

Evidence: The lab report (COA) confirms 7-Hydroxymitragynine on a dry-weight basis at 309.20 ppm, with an action limit of 400 ppm and a status of PASS — well below the Florida threshold. The test was performed under the 7OHFL section (7-Hydroxymitragynine - Florida - Dry-Weight Basis) by Cambium Analytica.

Ref: FL-893.03(1)(a)-7OH-400ppmThreshold

34. Side Effects Warning

Rule Summary: The label should warn of possible side effects such as nausea, dizziness, drowsiness and withdrawal symptoms.

Suggested Fix: Add a side-effects warning such as: 'Use of this product may cause nausea, dizziness, drowsiness or sedation, agitation, anxiety, hallucinations, breathing problems, rapid heart rate, seizures, and withdrawal symptoms.'

Ref: FL-WarningStatements-SideEffectsWarning-Recommended

35. Ingredient List

Rule Summary: Ingredients must be listed by common name in descending order of predominance by weight, with allergens declared.

Suggested Fix: The back panel lists "Other Ingredients: Microcrystalline Cellulose, Dicalcium Phosphate, Dextrose Monohydrate, Natural Flavoring, Silicone Dioxide, Sucralose, Magnesium Stearate" using common/usual names.

Ref: 21CFR101.4

36. Alkaloid Ratio Not Disclosed

Rule Summary: Passing with recommendation as the new rule 5KER26-11 is currently not strictly enforced for the first 60 days - compliant until October 23, 2026. From there, this requirement can be added to the QR code. The rule requires every label, regardless of 7-oh level, to state the mitragynine-to-7-oh alkaloid ratio in mg, as a whole integer (e.g., "alkaloid ratio 120 mg:1 mg").

Evidence: Neither the front nor back panel supplied contains an "alkaloid ratio" statement anywhere. The coa reports mitragynine at 107.81 mg/serving and 7-hydroxymitragynine at 0.17 mg/serving, which would compute to an approximate ratio of 634 mg : 1 mg (rounded up) — comfortably above the 100:1 minimum — but no such statement appears on the label as supplied.

Suggested Fix: Add a standalone "alkaloid ratio [mitragynine mg]:[7-oh mg]" statement to the label, e.g., "alkaloid ratio 634 mg:1 mg" (subject to counsel/lab confirmation of the rounding convention).

Ref: 5KER26-1(1)(1)/5KER26-1(2)(b)

REVIEWED FILES

Mighty Mango Back.pdf

Product Label 191.0 KB

3.75"

5.5"



SUPPLEMENT FACTS

Serving Size: ¼ Tablet 62.5 mg Servings per Container: 16	
Key Ingredients	Amount Per Serving
Mitragyna Speciosa	62.5 mg
Mitragynine	30 mg
Other Alkaloids	<1%
7-Hydroxymitragynine	309.20 parts per million (PPM) ON DRY WEIGHT BASES
Batch Number	027101006MG
Expiration Date	12/2028

Other Ingredients:
Microcrystalline Cellulose, Dicalcium Phosphate, Dextrose Monohydrate, Natural Flavoring, Silicone Dioxide, Sucralose, Magnesium Stearate.

Product Description: Tablets are made from premium Mitragyna Speciosa leaf extract, offering a refined and balanced formulation. Designed for adult use only, this product is not intended for daily consumption and should be used responsibly.

Usage Guidelines: Consume no more than one serving every 48 hours. Effects may be delayed by up to two hours. Store in a cool, dry place away from direct sunlight.

Safety & Legal Disclaimer: For adults 21+ only. Keep out of reach of children. Not a food product. Not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before use, especially if you have medical conditions or are taking medication. Do not use if pregnant, nursing, or operating heavy machinery. Manufacturer and resellers assume no liability for misuse of this product.

FDA Disclaimer: These products and statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

Legal Disclaimer / Liability Disclaimer: By using this product, you assume full responsibility for any adverse events and/or health complications that may result from its use. Manufacturer/reseller assumes no liability for the misuse of this product.




Manufactured for:
Moon Walker LLC
8 The Green Ste B
Dover DE 19901
contact@moonwalkerkratom.com



7 02940 82124 9

Mighty Mango Front.pdf

Product Label 144.0 KB



COA MIGHTY MANGO.pdf

Certificate of Analysis (COA) 530.6 KB

Certificate of Analysis

Sample Name: MOON WALKER KRATOM CHEWABLE TABLET 250MG MIGHTY MANGO

Client: Moon Walker Bota LLC

Sample Code: DTS-251212-012

Matrix Name: Pill - Tablet

Type / Result: Quality Assurance - Pass



Received Date: Mon, Dec 15, 2025

Published Date: Thu, Dec 18, 2025

Batch/Lot Code: 027101006MG

Batch Size: 5.90kg

Sample Size: 590mg/kg

Average Unit Weight: 0.584725g

RESULT SUMMARY

Mitragynine	108.92 mg /serv
Total Major Alkaloids	116.92 mg /serv

ALKU ✓ Kratom Alkaloids High Level	ALKL ✓ Kratom Alkaloids Low Level	MOS ✓ Moisture Content Loss on Drying	7OHFL ✓ 7-Hydroxymitragynine Florida
--	---	---	--

Approvals

RESULTS REVIEWED BY:

Leslie Varela **Leslie Varela** Cambium Analytica
Laboratory Director Thursday, Dec 18, 2025

RESULTS CERTIFIED BY:

Douglas Smith **Douglas Smith** Cambium Analytica
VP - Scientific Operations Thursday, Dec 18, 2025

This report may not be reproduced except in full without approval from Cambium Analytica. The results herein relate only to the sample & batch identified in this report.

Lab Information

Address: 1230 Woodmere Ave, Traverse City, MI 49686 **Phone:** 231.252.3669 **Accreditation:** ISO/IEC 17025:2017 – #108157



DTS-251212-012

2/2

ALKU

Kratom Alkaloids - High Level

LAB-TM-052 - Determination of Kratom Alkaloid Content by UPLC-DAD
ALKU-DTS-251212-012-01 - TUE, DEC 16, 2025

Analyte	Value	Value (mg/g)	Per Serving	Per Package	Action Limit	LOD	LOQ	Status
Mitragynine	18.6278 %	186.2783 mg/g	108.92 mg	108.92 mg	N/A	0.3 ug/g	0.5 ug/g	N/A
Paynantheine	0.8150 %	8.1499 mg/g	4.77 mg	4.77 mg	N/A	0.3 ug/g	0.5 ug/g	N/A
Speciogynine	0.4312 %	4.3117 mg/g	2.52 mg	2.52 mg	N/A	0.3 ug/g	0.5 ug/g	N/A
Speciociliatine	0.1222 %	1.2216 mg/g	0.71 mg	0.71 mg	N/A	0.3 ug/g	0.5 ug/g	N/A
Total Major Alkaloids*	19.9962 %	199.9616 mg/g	116.92 mg	116.92 mg	N/A	N/A	N/A	N/A

*Total Major Alkaloids is calculated as the sum of Mitragynine, Paynantheine, Speciociliatine and Speciogynine.

ALKL

Kratom Alkaloids - Low Level

LAB-TM-047 - Determination of Kratom Alkaloid Content by LC-TQ
ALKL-DTS-251212-012-01 - WED, DEC 17, 2025



Analyte	Value	Value (mg/g)	Per Serving	Per Package	Action Limit	LOD	LOQ	Status
7-Hydroxymitragynine	0.02959 %	0.29589 mg/g	0.17 mg	0.17 mg	N/A	0.002 ug/g	0.011 ug/g	N/A
Mitraphylline	0.00026 %	0.00257 mg/g	0.00 mg	0.00 mg	N/A	0.004 ug/g	0.019 ug/g	N/A
Total Minor Alkaloids*	0.02985 %	0.29846 mg/g	0.17 mg	0.17 mg	N/A	N/A	N/A	N/A

*Total Minor Alkaloids is calculated as the sum of 7-Hydroxymitragynine and Mitraphylline.

MOS

Moisture Content - Loss on Drying

LAB-TM-008 - Loss on Drying
MOS-DTS-251212-012-01 - THU, DEC 18, 2025



Analyte	Value	Action Limit	LOD	LOQ	Status
Moisture	4.30 %	N/A	N/A	N/A	N/A

7OHFL

7-Hydroxymitragynine - Florida - Dry-Weight Basis

7-Hydroxymitragynine - (Florida — Dry-Weight Basis)
7OHFL-DTS-251212-012-01 - THU, DEC 18, 2025

Analyte	Value	Action Limit	LOD	LOQ	Status
7-Hydroxymitragynine - As Received*	295.90 ppm	N/A	N/A	N/A	N/A
7-Hydroxymitragynine - Dry-Weight*	309.20 ppm	400 ppm	N/A	N/A	PASS
Moisture (%) by Input*	4.30 %	N/A	N/A	N/A	N/A

*7-Hydroxymitragynine - As Received: The "As Received" value represents the concentration of 7-hydroxymitragynine, expressed in parts per million (ppm), as reported in the Kratom Alkaloids - Low Level test. This corresponds to the measured percentage of 7-hydroxymitragynine in the sample as received.

*7-Hydroxymitragynine (Dry-Weight Basis): The dry weight concentration of 7-hydroxymitragynine is calculated using the following formula: Dry Weight 7-Hydroxymitragynine (ppm) = 7-Hydroxymitragynine (ppm) x (100 / (100 - Moisture by Input (%)))

*The Moisture (%) by Input result may represent either a client-provided input or a value measured by Cambium. This value is incorporated into associated calculated analytes for reporting purposes.





Review critical findings before resubmitting packaging materials.